Clinical trials: Sexually Transmitted Infection (STI)
HIV Infections
Immune Response to a Therapeutic HIV Vaccine Followed by Treatment Interruption in Patients With Acute or Recent HIV Infection
The purpose of this study is to determine whether the HIV vaccine MRKAd5 HIV-1 gag/pol/nef followed by treatment interruption can increase immune system function in adults with acute or recent HIV infection who have started…
- Trial name
- NCT00183261
- Testing
- MRKAd5 HIV-1 gag/pol/nef
- Where
- 23 sites in United States, American Samoa and 1 more
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection, Inflammation
The MISTRAL Study: Gut Microbiome Correlates of Serious AIDS and Non-AIDS Events
MISTRAL (Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications, antimicrobial drug resistance, and unresponsiveness to therapeutic HIV-1 vaccination) is a 5-year EU Horizon…
- Conditions
- HIV-1-infection, Inflammation, AIDS
- Trial name
- MISTRAL (NCT05421286)
- Where
- 22 sites in Belgium, Croatia and 9 more
- Volunteers
- 991 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Hepatitis C Virus (HCV)
A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection
This study will evaluate the efficacy and safety of glecaprevir/pibrentasvir (ABT-493/ABT-530) in non-cirrhotic chronic hepatitis C virus (HCV) genotype (GT)1 to GT6-infected Asian participants with or without human…
- Trial name
- VOYAGE-1 (NCT03222583)
- Testing
- Glecaprevir/Pibrentasvir
- Where
- 48 sites in China, Singapore and 1 more
- Volunteers
- 546 people
- Sponsor
- AbbVie
HIV Infections, Pregnancy
Active Immunization of HIV-1 Infected, Pregnant Women With CD4 Lymphocyte Counts >= 400/mm3: A Phase I Study of Safety and Immunogenicity of MN rgp120/HIV-1 Vaccine (NOTE: Some Patients Receive Placebo)
To evaluate the safety of rgp120/HIV-1MN vaccine in HIV-1 infected pregnant women with CD4 counts >= 400 cells/mm3. To evaluate the immunogenicity of this vaccine in pregnant women and the passive acquisition of vaccine-specific…
- Trial name
- NCT00001041
- Testing
- rgp120/HIV-1MN
- Where
- 6 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis Streptococcal, Hiv
Treatment With Tamoxifen in Cryptococcal Meningitis
The purpose of this study is to develop initial efficacy, feasibility, and safety data regarding the use of Tamoxifen in combination with amphotericin B and fluconazole in the treatment of cryptococcal meningitis.
- Conditions
- Meningitis Streptococcal, Hiv, Meningitis, Meningoencephalitis
- Trial name
- NCT03112031
- Testing
- Tamoxifen, Amphotericin B, Fluconazole
- Where
- 3 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
HIV Infections, HIV Seronegativity
ALVAC-HIV vCP1452 Alone and Combined With MN rgp120
The purpose of this study is to test how the body's immune system responds to the vaccine ALVAC-HIV vCP1452 and to determine if the vaccine is safe when given alone and with MN rgp120.
- Trial name
- NCT00011037
- Testing
- ALVAC(2)120(B,MN)GNP (vCP1452), MN rgp120/HIV-1
- Where
- 4 sites in Brazil, Haiti and 2 more
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
To evaluate the pharmacokinetics of Retrovir (AZT) administered orally as 1 of 3 doses in the treatment of patients with severe clinical and laboratory manifestations of HIV infection.
- Trial name
- NCT00002046
- Testing
- Zidovudine
- Where
- 11 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Medication Adherence, Methamphetamine Use
Intervention Targeting Medication Adherence and Methamphetamine Use in HIV Positive Men (ACE)
The primary aim is to test an innovative 8-session intervention, based on Motivational Interviewing and Cognitive Behavioral Skills-Training for the co-occurrence of methamphetamine use and highly active antiretroviral therapy…
- Conditions
- HIV Medication Adherence, Methamphetamine Use, Sexual Risk, Poly-substance Use
- Trial name
- ACE (NCT01122186)
- Testing
- Motivational Interviewing + Cognitive Behavioral Skills Training, Education Attention Control
- Where
- United States
- Volunteers
- 210 people
- Sponsor
- Hunter College of City University of New York
HIV Infection
HIV Reservoir Reduction With Interleukin-2
The purpose of this pilot study is to examine the effects of eight 4-day cycles of subcutaneous recombinant interleukin-2 (rIL-2) given every 8 weeks on levels of replication-competent HIV in CD4 cells and on the size of HIV…
- Trial name
- IL2 (NCT03308786)
- Testing
- Recombinant Interleukin-2
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Western Reserve University
HIV
Vaccination of HIV-1 Infected Patients With Dendritic Cells in Addition to Antiretroviral Treatment - (DALIA Trial)
The purpose of this study is to determine whether the administration of a dendritic cell vaccine is a safe and effective treatment for HIV-1 patients.
- Trial name
- NCT00796770
- Testing
- Dendritic Cell Vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Baylor Research Institute
HIV/AIDS, Sexually Transmitted Diseases
A Pilot Peer Mentor Intervention That Trains Black Men Who Have Sex With Men (BMSM) to Use and Promote Uptake of HIV/STI Self-Testing to Peers and Sex Partners: STAR Study (Self-Testing at Your Residence)
The objectives of the study are to assess the feasibility, reach and preliminary efficacy of a brief intervention that trains Black men who have sex with men [referred to as Index] (a) to use home-based testing for HIV and…
- Trial name
- STAR (NCT04121962)
- Testing
- Peer Mentor, Website only
- Where
- United States
- Volunteers
- 163 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
HIV Infections
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
This study assessed the safety and tolerability of enfuvirtide in participants with advanced HIV genotype 1 (HIV-1) disease. Eligible participants who failed treatment with regimens containing at least one product from each…
- Trial name
- NCT02582983
- Testing
- Enfuvirtide
- Where
- 5 sites in Thailand
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Genital Warts
Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts
Large genital warts are frequently diagnosed in general gynaecology and oncology clinics in South Africa. Medical and destructive therapy for small warts is generally very effective, however unique problems posed by large or…
- Trial name
- TheraVACCS (NCT02750202)
- Testing
- Quadrivalent HPV vaccine, Hepatitis B vaccine
- Where
- 2 sites in South Africa
- Volunteers
- 52 people
- Sponsor
- University of Pretoria
Human Immunodeficiency Virus
Cooperative Re-Engagement Controlled Trial (CoRECT)
CoRECT will help identify the important components of a data-sharing partnership between health departments and HIV care providers, and determine the extent to which a health department intervention can increase the number of…
- Trial name
- CoRECT (NCT02693145)
- Testing
- Anti-Retroviral Treatment and Access to Services (ARTAS)
- Where
- 3 sites in United States
- Volunteers
- 1,893 people
- Sponsor
- Centers for Disease Control and Prevention
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00474370
- Testing
- Vicriviroc
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV/AIDS
Rural PrEP Delivery
The goal of this research study is to evaluate the preliminary impact of a public-health-partnered tele-pharmacist model for pre-exposure prophylaxis (PrEP) delivery in a rural state ("TelePrEP").
- Trial name
- NCT03343223
- Testing
- Intervention Group
- Where
- United States
- Volunteers
- 234 people
- Sponsor
- Michael Ohl
HIV (Human Immunodeficiency Virus)
Boosting Olfactory and Sensory Training Study (BOOST)
The goal of this study is to examine two types of olfactory interventions (conventional olfactory training vs scented marker training) in adults with HIV. The two research questions are: 1.
- Trial name
- BOOST (NCT07221123)
- Testing
- Conventional Smell Training Group, Scented Marker Group
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
HIV/AIDS, Sexual Behavior
Reducing HIV Risk in Urban Women: Soap Opera Videos on Video-Capable Cell Phones
Background: Love, Sex, and Choices (LSC) is a soap opera video series created to reduce HIV sex risk in women. Methods: LSC was compared to text messages in a randomized trial in 238 high-risk mostly Black young urban women.
- Conditions
- HIV/AIDS, Sexual Behavior, Woman's Role, Risk Behavior
- Trial name
- NCT03330522
- Testing
- Love, Sex, & Choices video series, Messages in text
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Northeastern University
HIV Infections, Sexually Transmitted Diseases
HIV and STD Prevention for High-Risk, Inner-City, African American Youth
This study will evaluate the joint and separate effectiveness of two HIV/STD prevention programs in providing protection against acquiring STDs and maintaining safer sex behavior.
- Trial name
- NCT00353405
- Testing
- Social Skills Training, Mass media, Control
- Where
- 4 sites in United States
- Volunteers
- 1,650 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Cytomegalovirus Retinitis, HIV Infections
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002156
- Testing
- Fomivirsen sodium, Ganciclovir
- Where
- 18 sites in United States
- Volunteers
- 194 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.